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PRESENTATION of CASE
A
25-y-old woman presented with
pulmonary embolism. She had been
taking, without apparent complica-
tion, norgestimate/ethynil estradiol (Ortho
Tri-Cyclen; 0.180, 0.215, and 0.250 mg nor-
gestimate cycles and 35 lg ethinyl estradiol)
for 2 y, followed by the same drug combi-
nation but with a lower dose of ethinyl
estradiol (Ortho Tri-Cyclen Lo; 25 lg ethinyl
estradiol) for 14 mo. A nonsmoker, she lacked
a relevant family history and was vigorously
athletic.
One month prior to presentation, she
developed neck pain; disc protrusion at C5-
C6 was detected by magnetic resonance
imaging. The patient was prescribed valde-
coxib, 20 mg twice a day (b.i.d.), for 2 wk. Her
neck pain resolved. However, towards the
end of this treatment period, she developed
left-sided pleuritic chest and shoulder pain
after a 6-h car ride. She was started on
cyclobenzaprine, 10 mg b.i.d., and continued
on valdecoxib. Her left-sided pain abated
gradually. However, 18 d later, she developed
right-sided chest and shoulder pain. A
diagnosis of left iliac vein thrombosis and
bilateral pulmonary emboli was based on a
computed tomography scan. She was hepari-
nized and continued on therapy with warfar-
in, 5 mg b.i.d., and enoxaparin, 60 mg b.i.d.
Despite this, a ventilation-perfusion scan
performed 13 d later showed multiple
pulmonary emboli (Figure 1).
Currently, the patient is on warfarin, 2.5 mg
daily, while completing a 6-mo warfarin
regimen. Her warfarin is well tolerated and
otherwise the patient is in good health.
DISCUSSION
Coxibs, selective inhibitors of cyclooxyge-
nase-2 (COX-2), increase the risk of myocar-
dial infarction and stroke [1–3], prompting
concern for patients with established cardio-
vascular disease. Caution may also extend to
individuals predisposed to thrombosis by
genetic or environmental factors.
Risk factors for spontaneous thrombosis
include oral contraceptives, genetic predis-
position to a hypercoaguable state, and
prolonged periods of stasis [4–6]. At least
two risk factors pertained to this patient.
The patient had been taking oral contra-
ceptives for 3 y prior to the index event,
albeit without recognized thrombotic com-
plication. It is possible that despite this
extended period of apparent tolerance, the
embolic events were solely related to use of
the oral contraceptives [4].
The relatively small risk of venous throm-
boembolism attributable to oral contracep-
tive use may interact geometrically with the
similarly small absolute risk of a procoagulant
mutation, such as Factor V Leiden [5].
However, documented genetic risk factors,
such as abnormalities in lupus anticoagulant,
anti-thrombin III, proteins C and S, plasma
homocysteine, anticardiolipin, b2 glycopro-
tein antibody, and prothrombotic mutations
in Factor V and prothrombin were excluded.
It remains possible that the patient was
genetically predisposed to thrombosis by a
mutation in an undetermined factor.
Finally, prolonged stasis, such as that which
occurred during the 6-h car trip, may account
for the clinical event [6]. However, the
absolute risk is small, and the patient had
made this trip on multiple occasions devoid
of apparent clinical complications during the
prior 3 y.
The risk of thrombosis from valdecoxib has
now been established [3,7], and this, together
with its propensity rarely to cause Stevens-
Johnson syndrome without a mitigating ben-
eﬁt over traditional nonsteroidal anti-inﬂam-
matory drugs, has led to its withdrawal from
the market. The cardiovascular hazard of
coxibs appears likely to be attributable to the
suppression of COX-2-derived prostacyclin
[1,8]. Deletion of the prostacyclin receptor in
mice does not cause spontaneous thrombosis,
but rather enhances the response to throm-
botic stimuli [9]. This is consistent with the
fact that a cardiovascular signal from a coxib
is most easily detected in patients with
hemostatic activation, such as was observed
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undergoing cardiopulmonary bypass grafting [7] and anec-
dotally in patients with connective tissue disease [10].
Although this case does not establish a causative linkage
with valdecoxib, the clinical event was not manifest until
three potential risk factors were combined (oral contra-
ceptives, prolonged stasis, and coxib treatment). Given the
multiplicative interactions of risk factors for thromboem-
bolic disease and the apparently untoward concurrence of
two of them—the contraceptive pill and frequent road trips
for the preceding 3 y—the rapid occurrence of the clinical
event following initiation of the coxib suggests a causative
link to the COX-2 inhibitor. However, it also remains
formally possible that this temporal relationship was a
coincidence.
This case report has been reported to the regulatory
authorities and to the manufacturer of valdecoxib.
Just as the small absolute risks of thrombosis attributable to
oral contraceptives and prothrombotic mutations may
interact dramatically [5], selective inhibitors of COX-2 may
also interact with genetic and environmental factors that
predispose to the risk of thrombosis.
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Learning Points
 The risk of thrombotic events on COX-2 inhibitors may extend
to apparently healthy individuals.
 Genetic and environmental risk factors for thrombosis may
interact geometrically.
 Patients should be screened for recognized genetic or
environmental predisposition to thrombosis prior to deciding to
initiate treatment with COX-2 inhibitors.
Figure 1. Ventilation-Perfusion Scan
(A) After inhalation of 20.1 mCi of Xenon-133 gas, scintigraphic images
were obtained in the posterior projection, showing uniform ventilation
to lungs.
(B) After intravenous injection of 4.1 mCi of Technetium-99m-labeled
macroaggregated albumin, scintigraphic images were obtained, shown
here in the posterior projection. This and other views showed decreased
activity in the following regions: apical segment of right upper lobe,
anterior segment of right upper lobe, superior segment of right lower
lobe, posterior basal segment of right lower lobe, anteromedial basal
segment of left lower lobe, and lateral basal segment of left lower lobe.
DOI: 10.1371/journal.pmed.0020197.g001
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